Skip to main
OM
OM logo

Outset Medical (OM) Stock Forecast & Price Target

Outset Medical (OM) Analyst Ratings

Based on 3 analyst ratings
Buy
Strong Buy 67%
Buy 0%
Hold 33%
Sell 0%
Strong Sell 0%

Bulls say

Outset Medical Inc has demonstrated strong performance in console sales for Q3, surpassing expectations even amidst delays in significant orders, indicating a robust demand for its innovative Tablo system. The company is effectively progressing towards profitability and achieving its financial goals, including a target of less than $50 million in cash burn for 2025, while its adjusted gross margin of 39.8% exceeded both consensus and internal guidance. The favorable market dynamics, including a growing Tablo pipeline and accelerated consumables ordering, along with under-penetrated market opportunities, further position Outset Medical for long-term growth and success in the dialysis sector.

Bears say

Outset Medical Inc. is facing challenges that have adversely impacted its financial outlook, as evidenced by a lowered full-year revenue guidance by approximately $7 million and disappointing quarterly performance. Consumables revenue, typically a strong point for the company, showed weakness due to reduced orders from acute care customers, contributing to total revenues falling short at $29.4 million compared to expected figures. Furthermore, factors such as delays in enterprise deal timelines, a significant console order postponed to Q4, and the departure of the head of sales are raising concerns about future revenue consistency and operational stability.

Outset Medical (OM) has been analyzed by 3 analysts, with a consensus rating of Buy. 67% of analysts recommend a Strong Buy, 0% recommend Buy, 33% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Outset Medical and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Outset Medical (OM) Forecast

Analysts have given Outset Medical (OM) a Buy based on their latest research and market trends.

According to 3 analysts, Outset Medical (OM) has a Buy consensus rating as of Nov 26, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $16, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $16, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Outset Medical (OM)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.